[go: up one dir, main page]

WO1997037652B1 - Methodes de neuroprotection - Google Patents

Methodes de neuroprotection

Info

Publication number
WO1997037652B1
WO1997037652B1 PCT/US1997/005860 US9705860W WO9737652B1 WO 1997037652 B1 WO1997037652 B1 WO 1997037652B1 US 9705860 W US9705860 W US 9705860W WO 9737652 B1 WO9737652 B1 WO 9737652B1
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
human
administering
treating
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/005860
Other languages
English (en)
Other versions
WO1997037652A1 (fr
Filing date
Publication date
Priority claimed from US08/632,338 external-priority patent/US5728728A/en
Application filed filed Critical
Priority to AU24487/97A priority Critical patent/AU711963B2/en
Priority to JP9536455A priority patent/JP2000508318A/ja
Priority to EP97920250A priority patent/EP0914115A4/fr
Publication of WO1997037652A1 publication Critical patent/WO1997037652A1/fr
Publication of WO1997037652B1 publication Critical patent/WO1997037652B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

Nouvelles méthodes de traitement des maladies neurologiques aigües et chroniques asymptomatiques et d'enrayement de la mort des cellules neuronales dans les maladies neurologiques. Ces méthodes consistent à utiliser un antagoniste du site glycine au niveau du complexe NMDA (N-methyl-D-aspartate), par exemple un dicarbamate 2-phényl-1,3-propanodiol (felbamate).
PCT/US1997/005860 1996-04-10 1997-04-10 Methodes de neuroprotection Ceased WO1997037652A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU24487/97A AU711963B2 (en) 1996-04-10 1997-04-10 Methods of providing neuroprotection
JP9536455A JP2000508318A (ja) 1996-04-10 1997-04-10 神経細胞の保護方法
EP97920250A EP0914115A4 (fr) 1996-04-10 1997-04-10 Methodes de neuroprotection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/632,338 US5728728A (en) 1996-04-10 1996-04-10 Methods of providing neuroprotection
US08/632,338 1996-04-10

Publications (2)

Publication Number Publication Date
WO1997037652A1 WO1997037652A1 (fr) 1997-10-16
WO1997037652B1 true WO1997037652B1 (fr) 1997-11-13

Family

ID=24535118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005860 Ceased WO1997037652A1 (fr) 1996-04-10 1997-04-10 Methodes de neuroprotection

Country Status (6)

Country Link
US (4) US5728728A (fr)
EP (1) EP0914115A4 (fr)
JP (1) JP2000508318A (fr)
AU (1) AU711963B2 (fr)
CA (1) CA2251579A1 (fr)
WO (1) WO1997037652A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728728A (en) 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6310097B1 (en) * 1997-07-28 2001-10-30 Riken Protecting and survival promoting agent for central nervous cell
EP0982026B1 (fr) * 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Utilisation de dérivés d'aryl-cyclohexylamine dans la fabrication d'agents bloquants du récepteur NMDA
CA2360258A1 (fr) 1999-02-09 2000-08-17 Timothy L. Macdonald Composes derives du felbamate
US6555564B1 (en) * 1999-03-04 2003-04-29 The Board Of Trustees Of The University Of Illinois Neuropharmacological treatments of sleep-related breathing disorders
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
DE60017733T2 (de) * 1999-06-04 2006-01-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von riluzol zur behandlung multipler sklerose
US6653354B2 (en) * 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
AU2001261219B2 (en) * 2000-05-05 2005-08-25 University Of Virginia Patent Foundation Felbamate derived compounds
FR2809620B1 (fr) * 2000-06-05 2002-08-02 Aventis Pharma Sa Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1337218A4 (fr) * 2000-10-25 2005-08-10 Univ Virginia Composes derives de felbamate substitue
US6884777B1 (en) 2000-11-14 2005-04-26 The Nemours Foundation Method for treating respiratory distress syndrome
NZ527990A (en) * 2001-02-27 2006-01-27 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neurodegenerative disorders
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
US20040058997A1 (en) * 2002-09-24 2004-03-25 David Gordon Daniel Method for treatment of disorders of personal attachment and deficient social interaction
ES2862337T3 (es) 2003-03-04 2021-10-07 Lyotropic Therapeutics Inc Composiciones de dantroleno
FR2864535B1 (fr) * 2003-12-24 2006-12-22 Merck Sante Sas Derives acides de quinoline et leurs applications en therapeutique
AP2282A (en) * 2004-05-25 2011-10-31 Yates Petroleum Corp Methods of evaluating undersaturated caolbed methane reservoirs.
JP2006213611A (ja) * 2005-02-02 2006-08-17 Suzuka Univ Of Medical Science １‐アミノシクロプロパンカルボン酸等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤
JP2007246507A (ja) * 2006-02-15 2007-09-27 Kracie Seiyaku Kk 疲労の予防・治療組成物及び予防・治療方法
US9259419B2 (en) * 2006-07-10 2016-02-16 Synapsin Pharmaceuticals, Inc. Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA3067162A1 (fr) 2017-06-12 2018-12-20 Glytech Llc. Traitement de la depression avec des antagonistes du nmda et de la d2/5ht2a ou des antagonistes de la 5ht2a selectifs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292772A (en) * 1989-09-26 1994-03-08 Carter-Wallace, Inc. Method for the prevention and control of epileptic seizure associated with Lennox-Gastaut syndrome
US4978680A (en) * 1989-09-26 1990-12-18 Carter-Wallace, Inc. Method for the prevention and control of epileptic seizure
US5055489A (en) * 1990-05-04 1991-10-08 Carter-Wallace, Inc. Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events
US5256690A (en) * 1990-05-04 1993-10-26 Carter-Wallace, Inc. Method for treating and controlling the symptoms of neurodegenerative disease and neuropsychopharmacological disorders
WO1992021340A1 (fr) * 1991-06-05 1992-12-10 United States Of America, As Represented By The Secretary Of The Army Methode de traitement de l'encephalite infectieuse d'origine virale, bacterienne ou parasitaire
DK0531105T3 (fr) * 1991-09-03 1997-05-12 Carter Wallace
US5290808A (en) 1992-11-06 1994-03-01 Carter-Wallace, Inc. Method to control the intake of food
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection

Similar Documents

Publication Publication Date Title
WO1997037652B1 (fr) Methodes de neuroprotection
Capra et al. Light chain sequences of human IgM cold agglutinins
WO1999015553A3 (fr) Polypeptide costimulant de lymphocytes t, anticorps monoclonaux, leur production et leur utilisation
CA2182289A1 (fr) Anticorps monoclonaux immunostimulants
NO981712D0 (no) Syntetisk diesel brennstoff, samt fremgangsmÕte ved fremstilling derav
DE69830492D1 (de) Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME)
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
CA2127462A1 (fr) Traitement de l'asthme
CA2117492A1 (fr) Antigene de voisinage supprimant des maladies immunitaires
EP1439193A3 (fr) Anticorps contre la heparanase
WO1997019111A3 (fr) Anticorps monoclonaux anti-cd6 et leurs utilisations
AU5405196A (en) Synergistic process for improving combustion
AU1679795A (en) Anti-fungal methods and materials
GB9611269D0 (en) Fuel injection valve for i.c. engines
Jacob et al. Human systemic lupus erythematosus sera contain antibodies against cell-surface protein (s) that share (s) epitope (s) with DNA.
CA2173611A1 (fr) Procede de traitement du fonctionnement reduit du systeme reticulo-endothelial
Garb et al. Immune regulation in murine schistosomiasis japonica: inhibition of in vitro antigen-and mitogen-induced cellular responses by splenocyte culture supernatants and by purified fractions from serum of chronically infected mice.
CA2119128A1 (fr) Soulagement des symptomes associes aux etats inflammatoires aigus
AU4256096A (en) Monoclonal antibody fragments having immunosuppressant activity
CA2238278A1 (fr) Proteine antigenique provenant de la malassezia
EP1023906A4 (fr) Potentialisateur pour anticorps anti-tumeur lymphoide
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
Carding et al. Multiple proteins related to the soluble galactose-binding animal lectin revealed by a monoclonal anti-lectin antibody
Smith et al. Monoclonal antibodies to denatured ragweed pollen allergen Amb a I: characterization, specificity for the denatured allergen, and utilization for the isolation of immunogenic peptides of Amb a I
EP0700929A3 (fr) Peptides dérivés de allergènes du pollen de cèdre et leur applications